How To Write A Cer

Size: px
Start display at page:

Download "How To Write A Cer"

Transcription

1 2014 CBER Update: Advertising & Promotional Labeling Compliance Alpita Popat, PharmD, MBA Consumer Safety Officer Advertising & Promotional Labeling Branch Division of Case Management Office of Compliance and Biologics Quality

2 Agenda Organization Jurisdiction Submissions Compliance action Common violations New contact information 2

3 Advertising & Promotional Labeling Branch Lisa Stockbridge, Ph.D. (Branch Chief) Michael Brony, Pharm.D. CDR Oluchi Elekwachi, Pharm D. Kristine Khuc, Pharm.D. Dana Martin LCDR Loan Nguyen, Pharm.D. Alpita Popat, Pharm.D., M.B.A. CDR Sonny Saini, Pharm.D., M.B.A.

4 OCBQ Director, Mary Malarkey OCBQ - Deputy Director Mark Schwartz CBER/OCBQ/DCM/APLB Division of Case Management DCM Director, Bob Sausville Division of Inspections and Surveillance DIS Director, Gill Conley Division of Manufacturing and Product Quality DMPQ Director, Jay Eltermann DMPQ Deputy Director Laurie Norwood Division of Biological Standards and Quality Control DBSQC Director - Dr. Bill McCormick

5 CBER Products blood and blood components vaccines allergenic extracts human tissue & cellular products (cord blood) gene therapy products biological devices and test kits

6 Regulations for CBER Product Labeling 21 CFR and CFR CFR (container and package) 21 CFR 801 and 809 (biological devices) 21 CFR 1271 (cells, tissues)

7 Promotional Material FY10 - FY14 (through August 31, 2014)) FY10 FY11 FY12 FY13 FY Submissions

8 Material Types in

9 e-breakdown other banner banner e commerce website e mail e commerce mobile video social media social media mobile e mail video website other

10 2009 vs % 40% Internet Sales Aid Television Broadcast

11 Compliance Actions

12 Vampire Facelift

13 RegenKit -THT Website Patient brochure RegenPlasma TM Unleashed! Professional Brochure RegenPlasma TM Unleash the Power of PRP in Your Practice!

14 RegenKit THT (continued)

15 RegenKit -THT Claims With a simple, quick and advantageous RegenLab process, your own blood is safely prepared on the physician s premises and is delivered to your skin within the same treatment session. RegenPlasma is regenerative medicine and works best aesthetically when it is introduced into the skin. The use of RegenPlasma has long been known in a variety of aesthetic, surgical and wound care fields of medicine. RegenPlasma is a carefully designed leading edge product that has been scientifically verified for aesthetic applications The results have proven to be superior!

16 RegenKit -THT Instructions for Use The RegenKit THT is designed to be used for the safe and rapid preparation of autologous platelet rich plasma (PRP) from a small sample of blood at the patient s point of care. The PRP is mixed with autograft and/or allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.

17 RegenKit -THT Untitled Letter Adulterated Because there is no approved premarket application (PMA) or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. 360j(g) for the new intended uses of this device. Misbranded Because there has been no notice or other information with respect to the new intended uses for the device provided to FDA, as required by section 510(k) of the Act, 21 U.S.C. 360(k). Claims concerning use in cosmetic surgery are evidence of intended uses that are not consistent with the 510(k) clearance for RegenKit THT and represent a major change or modification in the intended use that requires the submission of a PMA or a 510(k).

18 Most Common Violations Indication Risk Efficacy 18

19 Resources Guidances oryinformation/default.htm uidances/default.htm Compliance Letters APLB Website s/advertisinglabelingpromotionalmaterials/ucm htm

20 NEW Contact Information Food and Drug Administration Center for Biologics Evaluation and Research Document Control Center New Hampshire Ave WO71 G112 Silver Spring, MD Phone:

21

Guidance for Industry

Guidance for Industry Guidance for Industry Promoting Medical Products in a Changing Healthcare Environment; I. Medical Product Promotion by Healthcare Organizations or Pharmacy Benefits Management Companies (PBMs) DRAFT GUIDANCE

More information

[DOCKET NO.96N-0002] DRAFT

[DOCKET NO.96N-0002] DRAFT [DOCKET NO.96N-0002] DRAFT DRAFT DOCUMENT CONCERNING THE REGULATION OF PLACENTAL/UMBILICAL CORD BLOOD STEM CELL PRODUCTS INTENDED FOR TRANSPLANTATION OR FURTHER MANUFACTURE INTO INJECTABLE PRODUCTS DECEMBER,

More information

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Frequently Asked Questions About Medical Devices Additional copies are available from: Office of Good Clinical Practice Office

More information

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY JOYCE R. BRANDA Acting Assistant Attorney General JONATHAN F. OLIN Deputy Assistant Attorney General Civil Division U.S. Department of Justice PAUL J. FISHMAN United States Attorney District of New Jersey

More information

ISCT Cell Therapy Liaison Meeting AABB Headquarters in Bethesda, MD. Regulatory Considerations for the Use of Software for Manufacturing HCT/P

ISCT Cell Therapy Liaison Meeting AABB Headquarters in Bethesda, MD. Regulatory Considerations for the Use of Software for Manufacturing HCT/P ISCT Cell Therapy Liaison Meeting AABB Headquarters in Bethesda, MD September 10, 2009 David Doleski, Team Leader, Branch 2 Division of Manufacturing and Product Quality (DMPQ) Office of Compliance and

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)

Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program

Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes

More information

FDA Regulation of Hearing Aids. Eric A. Mann, MD, PhD Clinical Deputy Director Division of Ophthalmic and ENT Devices ODE/CDRH/FDA

FDA Regulation of Hearing Aids. Eric A. Mann, MD, PhD Clinical Deputy Director Division of Ophthalmic and ENT Devices ODE/CDRH/FDA FDA Regulation of Hearing Aids Eric A. Mann, MD, PhD Clinical Deputy Director Division of Ophthalmic ENT ODE/CDRH/FDA U.S. Food Drug Administration Presentation Outline Overview of device regulations riskbased

More information

July 24, 2015. Dear Ms. Rhodes:

July 24, 2015. Dear Ms. Rhodes: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 InnoVision, Incorporated

More information

OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G

OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G Vada Perkins, BSN, MSc, RN CAPT, USPHS, Chief, Business Operations Staff US Food and Drug Administration OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G "Reviewed April 2013" 2D

More information

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special

More information

February 5, 2015. Dear Kristin Pabst,

February 5, 2015. Dear Kristin Pabst, DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 February 5, 2015, Inc.

More information

University of Texas Medical School at Houston. April 14, 2015

University of Texas Medical School at Houston. April 14, 2015 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 University of Texas Medical

More information

September 25, 2014. Dear Ms. McCoy:

September 25, 2014. Dear Ms. McCoy: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 September 25, 2014 Biomet

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Materials for Human Prescription Drugs Guidance for Industry DRAFT GUIDANCE This guidance document

More information

Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide

Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide U.S. Department of Health and Human Services Center for Drug Evaluation and

More information

March 3, 2015. Dear Ms. Alice Gong,

March 3, 2015. Dear Ms. Alice Gong, DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Jiangsu Ideal Medical

More information

October 28, 2015. Cavex Holland Bv Mr. Richard Woortman Manager Technical Services Fustweg 5 Haarlem, 2031CJ The NETHERLANDS

October 28, 2015. Cavex Holland Bv Mr. Richard Woortman Manager Technical Services Fustweg 5 Haarlem, 2031CJ The NETHERLANDS DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 October 28, 2015 Cavex

More information

August 21, 2015. TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom

August 21, 2015. TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Mr. Iain Alligan Technical

More information

Guidance for Industry Bar Code Label Requirements Questions and Answers

Guidance for Industry Bar Code Label Requirements Questions and Answers Guidance for Industry Bar Code Label Requirements Questions and Answers For questions on the content of this guidance, contact the Center for Drug Evaluation and Research or the Center for Biologics Evaluation

More information

DICOM Grid, Inc. January 25, 2016. Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314

DICOM Grid, Inc. January 25, 2016. Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 DICOM Grid, Inc. Senior

More information

Request for Quality Metrics Guidance for Industry

Request for Quality Metrics Guidance for Industry Request for Quality Metrics Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed

More information

Guidance for Industry Consumer-Directed Broadcast Advertisements

Guidance for Industry Consumer-Directed Broadcast Advertisements Guidance for Industry Consumer-Directed Broadcast Advertisements U.S. Department of Health and Human Services Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research

More information

August 18, 2015. Re: Section 1201 Rulemaking Proposed Exemption for Medical Devices

August 18, 2015. Re: Section 1201 Rulemaking Proposed Exemption for Medical Devices DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 August 18, 2015 Ms. Jacqueline C. Charlesworth General Counsel

More information

February 22, 2015. Life Spine, Incorporated Mr. Randy Lewis General Manager 2401 West Hassell Road, Suite 1535 Hoffman Estates, Illinois 60169

February 22, 2015. Life Spine, Incorporated Mr. Randy Lewis General Manager 2401 West Hassell Road, Suite 1535 Hoffman Estates, Illinois 60169 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 February 22, 2015 Life Spine, Incorporated Mr. Randy

More information

Unique Device Identification System: Small Entity Compliance Guide Guidance for Industry and Food and Drug Administration Staff

Unique Device Identification System: Small Entity Compliance Guide Guidance for Industry and Food and Drug Administration Staff Unique Device Identification System: Small Entity Compliance Guide Guidance for Industry and Food and Drug Administration Staff Document issued on August 13, 2014 On November 5, 2014 this document was

More information

May 7, 2015. Tactile Systems Technology Inc Daniel Chase V.P. Engineering & Operations 1331 Tyler St NE Minneapolis, Minnesota 55413

May 7, 2015. Tactile Systems Technology Inc Daniel Chase V.P. Engineering & Operations 1331 Tyler St NE Minneapolis, Minnesota 55413 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 May 7, 2015 Tactile Systems Technology Inc Daniel

More information

US Regulations for Import and Export of Cell Therapy Products

US Regulations for Import and Export of Cell Therapy Products US Regulations for Import and Export of Cell Therapy Products Kurt Gunter, MD U Minnesota UCB Transplants (2001-2007)* Total units: 790 Number US banks: 19 Number non-us banks: 12 % units from non-us banks:

More information

January 12, 2016. Dear Amy Yang:

January 12, 2016. Dear Amy Yang: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 January 12, 2016 Amy

More information

Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection

Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection U.S. Department of Health and Human Services Food and Drug Administration Office of Regulatory

More information

May 22, 2015. Rachel s Remedies, LLC Mrs. Rachel E. Jackson 2316 Delaware Ave. #174 Buffalo, New York 14216

May 22, 2015. Rachel s Remedies, LLC Mrs. Rachel E. Jackson 2316 Delaware Ave. #174 Buffalo, New York 14216 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 May 22, 2015 Rachel s

More information

Q(K SVJM~jPagelIof 3

Q(K SVJM~jPagelIof 3 K13 0460 Q(K SVJM~jPagelIof 3 JUL 1 12013 This 51 0(k) Summary is being submitted in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content contained in this 510(k)

More information

Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors

Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors This document is scheduled to be published in the Federal Register on 01/08/2016 and available online at http://federalregister.gov/a/2016-00149, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages FINAL GUIDANCE U.S. Department of Health and Human Services Food

More information

Use of Electronic Health Record Data in Clinical Investigations

Use of Electronic Health Record Data in Clinical Investigations Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

ORACLE CONSULTING GROUP

ORACLE CONSULTING GROUP ORACLE CONSULTING GROUP An Official United States Agent Firm for Foreign Establishments CONSULTING MEMORANDUM: DEALING WITH A MEDICAL DEVICE IN THE U.S. 5398 Golder Ranch Rd., Ste. 1 Tucson, Arizona 85739

More information

August 12, 2014. Oertli Instrumente AG Ms. Karin Rohr Head of Quality Management & Regulatory Affairs Hafnerwisenstrasse 4 CH 9442 Berneck Switzerland

August 12, 2014. Oertli Instrumente AG Ms. Karin Rohr Head of Quality Management & Regulatory Affairs Hafnerwisenstrasse 4 CH 9442 Berneck Switzerland DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service August 12, 2014 Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 Oertli

More information

Ad-tech Medical Instrument Corporation. Principal Consultant Quality & Regulatory Associates, LLC. 800 Levanger Lane. Stoughton, Wisconsin 53589

Ad-tech Medical Instrument Corporation. Principal Consultant Quality & Regulatory Associates, LLC. 800 Levanger Lane. Stoughton, Wisconsin 53589 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service March 4, 2016 Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Ad-tech

More information

May 5, 2015. Dear Mr. Courtney:

May 5, 2015. Dear Mr. Courtney: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 May 5, 2015 Terumo Cardiovascular

More information

November 20, 2014. Vascular Flow Technologies Ltd. Edwin Lindsay VP of QA/RA Prospect Business Centre, Gemini Cresent Dundee DD2 1TY United Kingdom

November 20, 2014. Vascular Flow Technologies Ltd. Edwin Lindsay VP of QA/RA Prospect Business Centre, Gemini Cresent Dundee DD2 1TY United Kingdom DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 November 20, 2014 Vascular

More information

Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff

Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Document issued on August 20, 2014. On November 5, 2014 this document was

More information

Providing Regulatory Submissions In Electronic Format Standardized Study Data

Providing Regulatory Submissions In Electronic Format Standardized Study Data Providing Regulatory Submissions In Electronic Format Standardized Study Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Phoenix Thera-Lase Systems, LLC Ms. Diane Rutherford Ken Block Consulting 1201 Richardson Drive, Suite 280 Richardson, Texas 75080

Phoenix Thera-Lase Systems, LLC Ms. Diane Rutherford Ken Block Consulting 1201 Richardson Drive, Suite 280 Richardson, Texas 75080 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 Phoenix Thera-Lase Systems,

More information

Contains Nonbinding Recommendations

Contains Nonbinding Recommendations FY 2016 Medical Device User Fee Small Business Qualification and Certification Guidance for Industry, Food and Drug Administration Staff and Foreign Governments Document issued on August 3, 2015. As of

More information

0 EC2 92011 V-,) 133 Lj9a

0 EC2 92011 V-,) 133 Lj9a 0 EC2 92011 V-,) 133 Lj9a Section 5: 5 1 0(k) Summar 5 10(K) SUMMARY FOR SOMATOM DEFINITION Flash (with Stellar Detector) Submitted by: Siemens Medical Solutions USA, Inc. 51 Valley Stream Parkway Malvern,

More information

How To Know If You Can Get A Blood Test For Hct/P

How To Know If You Can Get A Blood Test For Hct/P FDA/CBER Compliance Update EBAA Leadership and Advocacy Meeting February 13, 2014 Mary Malarkey, Director Office of Compliance and Biologics Quality Summary Registration Inspections Regulatory Actions

More information

FDA Considerations Regarding Frequent Plasma Collection Procedures

FDA Considerations Regarding Frequent Plasma Collection Procedures FDA Considerations Regarding Frequent Plasma Collection Procedures Alan E. Williams, Ph.D. Office of Blood Research and Review Center for Biologics Evaluation and Research US Food and Drug Administration

More information

I~r it NOV 72012. SIE T AENCORE Tongue Suspension System OCE 1 --. L_ August 3,2012. 510(k) Summary. Appendix 3:

I~r it NOV 72012. SIE T AENCORE Tongue Suspension System OCE 1 --. L_ August 3,2012. 510(k) Summary. Appendix 3: I~r it NOV 72012 510(k) for the Siesta Medical, Inc.1 SIE T AENCORE Tongue Suspension System OCE 1 --. L_ August 3,2012 Appendix 3: 510(k) Summary General Company Infomto Name: Contact: Siesta Medical,

More information

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-D-0798] Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communication Devices;

More information

Case 1:15-cv-23419-XXXX Document 1 Entered on FLSD Docket 09/10/2015 Page 1 of 8

Case 1:15-cv-23419-XXXX Document 1 Entered on FLSD Docket 09/10/2015 Page 1 of 8 Case 1:15-cv-23419-XXXX Document 1 Entered on FLSD Docket 09/10/2015 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF FLORIDA UNITED STATES OF AMERICA, ) ) Plaintiff, ) ) v.

More information

June 9, 2015. Stryker Corporation Garry T. Hayeck, Ph.D. Senior Regulatory Affairs Specialist 2 Pearl Court Allendale, New Jersey 07401

June 9, 2015. Stryker Corporation Garry T. Hayeck, Ph.D. Senior Regulatory Affairs Specialist 2 Pearl Court Allendale, New Jersey 07401 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 Stryker Corporation Garry

More information

Medical Device Reporting. Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration

Medical Device Reporting. Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration Medical Device Reporting Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration Session Overview Purpose: To provide information about the

More information

Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.

Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50. Guidance for Sponsors, Investigators, and Institutional Review Boards Questions and Answers on Informed Consent Elements, 21 CFR 50.25(c) (Small Entity Compliance Guide) U.S. Department of Health and Human

More information

Lewis Ward L.W. Ward and Associates, Inc. 4655 Kirkwood Court Boulder, CO 80301 303-530-3279

Lewis Ward L.W. Ward and Associates, Inc. 4655 Kirkwood Court Boulder, CO 80301 303-530-3279 510(k) Summary i '\' Submitted by Contact Person: EZ-Blocker B.V. Delftechpark 26 Delft 2628 XH 2, The Netherlands6911 Lewis Ward L.W. Ward and Associates, Inc. 4655 Kirkwood Court Boulder, CO 80301 303-530-3279

More information

Plamena Entcheva-Dimitrov, PhD, RAC On-line Course. www.preferredregulatoryconsulting.com 1

Plamena Entcheva-Dimitrov, PhD, RAC On-line Course. www.preferredregulatoryconsulting.com 1 Plamena Entcheva-Dimitrov, PhD, RAC On-line Course 1 The Preferred Regulatory Consulting content in this presentation is copyright protected under United States law and applicable international copyright

More information

Medical Billing and Agency Formal Disputes

Medical Billing and Agency Formal Disputes Guidance for Industry Formal Dispute Resolution: Appeals Above the Division Level Additional copies of this Guidance are available from: Office of Training and Communications Division of Communications

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Medication Guides Adding a Toll-Free Number for Reporting Adverse Events U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research

More information

Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products

Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Combination Products Regulation in the United States

Combination Products Regulation in the United States Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction

More information

GE Healthcare MAR 1 2013

GE Healthcare MAR 1 2013 K130155 Pagel1 of 2 GE Healthcare MAR 1 2013 510(k) Summary In accordance with 21 CFR 807.92 the following summary of information is provided: Submitter: Primary Contact Person: Secondary Contact Person:

More information

CTC Technology Readiness Levels

CTC Technology Readiness Levels CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.

More information

13. 510(k)Suminary k121917-0

13. 510(k)Suminary k121917-0 Hsiner Multiple CPAP Device 510(k) Submission JL1621 13. 510(k)Suminary k121917-0 In accordance with 21 CFR section 807.92 Hsiner is submitting the following 5 10(k) summary. 13.1. Date: 07/11/2012 13.2.

More information

UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES

UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES In the Matter of Dendy Foods, Inc. d/b/a Grocer s Pride ADMINISTRATIVE COMPLAINT FOR CIVIL MONEY

More information

LifeNet Health Presented by James Clagett, PhD., Chief Science Officer LifeNet Health - The Best Keep Secret in Regenerative Medicine

LifeNet Health Presented by James Clagett, PhD., Chief Science Officer LifeNet Health - The Best Keep Secret in Regenerative Medicine Presented by James Clagett, PhD., Chief Science Officer - The Best Keep Secret in Regenerative Medicine Corporate Headquarters Virginia Beach, VA Who is? helps save lives and restore health for thousands

More information

Simpler Implant Solutions Inc. 2930 Arbutus St. Vancouver, BC V6i 3Y9. haroldbergmanl~ogmail.com 604 736 9890 Telephone 604 736 9747 Fax K080115

Simpler Implant Solutions Inc. 2930 Arbutus St. Vancouver, BC V6i 3Y9. haroldbergmanl~ogmail.com 604 736 9890 Telephone 604 736 9747 Fax K080115 APR 5 2013 Summary: K121281 Submitter: Company Address Contact Person: Simpler Implant Solutions Inc. 2930 Arbutus St. Vancouver, BC V6i 3Y9 Dr. Harold Bergman haroldbergmanl~ogmail.com 604 736 9890 Telephone

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions

More information

April 3, 2015. Dear Autumn Liu,

April 3, 2015. Dear Autumn Liu, DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 April 3, 2015 Shenzhen

More information

Introduction to Compliance with FDA Labeling and Advertising Requirements

Introduction to Compliance with FDA Labeling and Advertising Requirements Introduction to Compliance with FDA Labeling and Advertising Requirements Second Annual Pharmaceutical Industry Regulatory and Compliance Summit Dick Kenny FDA History Basic function of government Oldest

More information

Section 5-510(k) Summary. This document is provided in the following pages. DEC 2 92010

Section 5-510(k) Summary. This document is provided in the following pages. DEC 2 92010 Section 5-510(k) Summary This document is provided in the following pages. DEC 2 92010 DC221 510(k) SUMMARY This summary of 5 10(k) safety and effectiveness information is being submitted in accordance

More information

Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation

Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation Leslie M. Tector Quarles & Brady LLP September 30, 2014 Objectives Which federal

More information

510(K) SUMMARY. 510(k) Number KOS'00-r

510(K) SUMMARY. 510(k) Number KOS'00-r " iirtual Ports Virtsua Ports Virtual Ports Ltd. 510(K) SUMMARY 510(k) Number KOS'00-r MAR 2 12008 Applicant's Name: Contact Person: Trade Name: Common name: Classification: Predicate Devices: Device Description:

More information

Guidance for Industry

Guidance for Industry Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center

More information

April 7, 2015. Acclarent, Inc. Mr. James Patrick Garvey II Sr. Manager, Regulatory Affairs 1525-B O'Brien Drive Menlo Park, CA 94025

April 7, 2015. Acclarent, Inc. Mr. James Patrick Garvey II Sr. Manager, Regulatory Affairs 1525-B O'Brien Drive Menlo Park, CA 94025 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 April 7, 2015 Acclarent,

More information

David M. Stern, M.D. JAN 2 9 7007 Dean, University of Cincinnati College of Medicine 231 Albert Sabin Way Cincinnati, OH 45267

David M. Stern, M.D. JAN 2 9 7007 Dean, University of Cincinnati College of Medicine 231 Albert Sabin Way Cincinnati, OH 45267 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Serv ice Food and Drug Administration 9200 Corporate Boulevard Rockville, Ma ry land 20850 WARNING LETTER VIA FEDERAL EXPRESS David M. Stern, M.D. JAN

More information

WARNING LETTER. Multikine is an investigational new drug that does not have marketing authorization in the United States. (b) (4)

WARNING LETTER. Multikine is an investigational new drug that does not have marketing authorization in the United States. (b) (4) DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Geert R. Kersten Director and Chief Executive Officer 8229 Boone

More information

UNITED STATES OF AMERICA BEFORE THE DEPARTMENTAL APPEALS BOARD CIVIL REMEDIES DIVISION DEPARTMENT OF HEALTH AND HUMAN SERVICES

UNITED STATES OF AMERICA BEFORE THE DEPARTMENTAL APPEALS BOARD CIVIL REMEDIES DIVISION DEPARTMENT OF HEALTH AND HUMAN SERVICES UNITED STATES OF AMERICA BEFORE THE DEPARTMENTAL APPEALS BOARD CIVIL REMEDIES DIVISION DEPARTMENT OF HEALTH AND HUMAN SERVICES In the Case of: Center for Tobacco Products, Complainant, v. NNMK Inc. d/b/a

More information

Formal FDA Meeting Request: Guidance and Template

Formal FDA Meeting Request: Guidance and Template Formal FDA Meeting Request: Guidance and Template ICTR Navigators July 23, 2011 Version 2.0 Page 1 of 20 1.0 Table of Contents Section Page 1.0 Table of Contents 2 2.0 Abbreviations 2 3.0 FDA Regulations

More information

DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers

DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for

More information

Guidance for Industry Classifying Resubmissions in Response to Action Letters

Guidance for Industry Classifying Resubmissions in Response to Action Letters Guidance for Industry Classifying Resubmissions in Response to Action Letters U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H--MEDICAL DEVICES

TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H--MEDICAL DEVICES [Code of Federal Regulations] [Title 21, Volume 8] [Revised as of April 1, 2010] [CITE: 21CFR807] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES

More information

Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO

Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO This document is scheduled to be published in the Federal Register on 05/29/2014 and available online at http://federalregister.gov/a/2014-12349, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Determination of Regulatory Review Period for Purposes of Patent Extension;

Determination of Regulatory Review Period for Purposes of Patent Extension; This document is scheduled to be published in the Federal Register on 12/15/2015 and available online at http://federalregister.gov/a/2015-31400, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Brainreader ApS February 4, 2015 C/O Mette Munch QA Consultant Skagenvej 21 Egaa, 8250 DENMARK

Brainreader ApS February 4, 2015 C/O Mette Munch QA Consultant Skagenvej 21 Egaa, 8250 DENMARK DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Brainreader ApS February

More information

Guidance for Industry. Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products

Guidance for Industry. Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products Guidance for Industry Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products Small Entity Compliance Guide Written comments and suggestions may be

More information

L~l t l V~! MAY 23 200?

L~l t l V~! MAY 23 200? L~l t l V~! MAY 23 200? 510 (k) Summay (As required by 21 CFR 807.92 and 21 CFR 807.93) NAME OF SPONSOR: 510(K) CONTACT: DePuy Orthopaedics, Inc. 700 Orthopaedic Drive Warsaw, Indiana 46582 Establishment

More information

Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA

Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions

More information

Consumer Representative Members Public Meeting. CDR Dornette Spell-LeSane, MHA, MSN, NP-C. Rockville, MD 30 April 2010. Deputy Director, ACOMS

Consumer Representative Members Public Meeting. CDR Dornette Spell-LeSane, MHA, MSN, NP-C. Rockville, MD 30 April 2010. Deputy Director, ACOMS Consumer Representative Members Public Meeting CDR Dornette Spell-LeSane, MHA, MSN, NP-C Deputy Director, ACOMS Rockville, MD 30 April 2010 E- mail address is dornette.spelllesane @ fda.hhs.gov Major points

More information

Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant

Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human

More information

Medical Devices; Cardiovascular Devices; Classification of the Esophageal Thermal Regulation

Medical Devices; Cardiovascular Devices; Classification of the Esophageal Thermal Regulation This document is scheduled to be published in the Federal Register on 08/18/2015 and available online at http://federalregister.gov/a/2015-20317, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

The draft of this document issued on December 27, 2011.

The draft of this document issued on December 27, 2011. The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)] Guidance for Industry and Food and Drug Administration Staff Document issued on: July 28, 2014 The draft of this

More information

Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry

Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for

More information

IQ Corporation c/o Harold G. Haines, Ph.D. President SEP 1 f 2002 South Florida BioAssociates, Inc. 11511 SW 127h Street Miami, Florida 33 176

IQ Corporation c/o Harold G. Haines, Ph.D. President SEP 1 f 2002 South Florida BioAssociates, Inc. 11511 SW 127h Street Miami, Florida 33 176 **,lo 4 DEPARTMENT OF HEALTH & HUMAN SERVICES IQ Corporation c/o Harold G. Haines, Ph.D. President SEP 1 f 2002 South Florida BioAssociates, Inc. 11511 SW 127h Street Miami, Florida 33 176. Food and Drug

More information

Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products

Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products Reprinted from FDA s website by EAS Consulting Group, LLC Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products DRAFT GUIDANCE This guidance document

More information

510(K) SUMMARY [as required by section 807.92(c)] FLIGHT 60 Ventilator 510(k) Number K IaO?2Z, JUL 6 2012

510(K) SUMMARY [as required by section 807.92(c)] FLIGHT 60 Ventilator 510(k) Number K IaO?2Z, JUL 6 2012 510(K) SUMMARY [as required by section 807.92(c)] FLIGHT 60 Ventilator 510(k) Number K IaO?2Z, JUL 6 2012 Date Prepared: March 7, 2012 Applicant's Name: Flight Medical Innovations Ltd. 13 Hamelacha Street

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Guidance for Industry Internet/Social Media Platforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document

More information

Plasmax Plasma Concentration System BIOLOGICS

Plasmax Plasma Concentration System BIOLOGICS Plasmax Plasma Concentration System BIOLOGICS Plasmax Plasma Concentration System Plasmax Plasma Concentrate System Contains Plasmax concentrator GPS III separator Provides 16ml of autologous output, 6ml

More information